| Halaven (eribulin mesylate) / Eisai |
NCT00097721: A Study of E7389 in Advanced/Metastatic Breast Cancer Patients |
|
|
| Completed | 2 | 104 | US | E7389 | Eisai Inc. | Breast Neoplasms | 11/06 | 11/06 | | |
NCT00246090 / 2005-003656-35: A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine |
|
|
| Completed | 2 | 298 | US, Canada | E7389 | Eisai Inc., Eisai Limited | Breast Cancer | 09/07 | 09/07 | | |
NCT00965523: Study of E7389 for Advanced or Metastatic Breast Cancer |
|
|
| Completed | 2 | 81 | Japan | Eribulin Mesylate | Eisai Co., Ltd. | Breast Cancer | 12/10 | 01/11 | | |
NCT01268150: A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer |
|
|
| Completed | 2 | 56 | US | Eribulin mesylate | Eisai Inc. | Locally Recurrent, Metastatic Breast Cancer ( HER2 Negative) | 03/12 | 08/13 | | |
EMERGE, NCT01156753: A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer |
|
|
| Completed | 2 | 120 | US | CDX-011, "Investigator's Choice" chemotherapy | Celldex Therapeutics | Breast Cancer | 10/12 | 11/12 | | |
|
|
|
|
NCT01269346: Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer |
|
|
| Completed | 2 | 52 | US | Eribulin Mesylate | Eisai Inc. | Breast Cancer | 03/13 | 05/16 | | |
|
NCT01427933: A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer |
|
|
| Completed | 2 | 141 | US | Ramucirumab (IMC-1121B), LY3009806, Eribulin | Eli Lilly and Company | Breast Cancer | 09/13 | 06/14 | | |
|
|
| Terminated | 2 | 7 | US, Europe | AEZS-108, Zoptarelin doxorubicin, SCCC, Standard single agent cytotoxic chemotherapy, Dexamethasone | AEterna Zentaris | Breast Cancer | 08/14 | 10/14 | | |
| Completed | 2 | 61 | Europe | Eribulin, Drug: Bevacizumab | ARCAGY/ GINECO GROUP | Metastatic Breast Cancer | 08/14 | 03/16 | | |
NCT01527487: Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer |
|
|
| Completed | 2 | 76 | US | Eribulin, Halaven, Cyclophosphamide, Cytoxan, Docetaxel, Taxotere | SCRI Development Innovations, LLC, Eisai Inc. | HER2 Negative Breast Cancer | 09/14 | 07/16 | | |
| Terminated | 2 | 43 | Europe | Lapatinib + 1,23 mg Eribulin, Lapatinib + 1,76 mg Eribulin | German Breast Group | Metastatic Breast Cancer | 03/15 | 03/15 | | |
NCT01498588: Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer |
|
|
| Terminated | 2 | 7 | US | Eribulin, Halaven, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan, Pegfilgrastim, Neulasta | Emory University, Eisai Inc. | Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast | 06/15 | 06/15 | | |
| Completed | 2 | 163 | Europe | Eribulin, Halaven(R) | SOLTI Breast Cancer Research Group, Eisai Inc. | Breast Cancer | 06/15 | 06/15 | | |
| Completed | 2 | 83 | US | Eribulin, E7389, Halaven, ER-086526, NSC-707389 | Dana-Farber Cancer Institute | Breast Cancer | 05/16 | 05/16 | | |
NCT01912963: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer |
|
|
| Terminated | 2 | 32 | US | Pertuzumab, Perjeta, Trastuzumab, Herceptin, eribulin, eribulin mesylate, Halaven | Dana-Farber Cancer Institute, Eisai Inc., Genentech, Inc. | HER2-positive Breast Cancer, Metastatic Breast Cancer | 12/16 | 12/16 | | |
NCT02481050: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer |
|
|
| Completed | 2 | 58 | US | Eribulin Mesylate, Halaven, E7389 | Eisai Inc. | Breast Cancer | 12/16 | 09/17 | | |
NCT01401959: Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy |
|
|
| Completed | 2 | 127 | US | Eribulin, Halaven, Trastuzumab, Herceptin | SCRI Development Innovations, LLC, Eisai Inc. | Metastatic Breast Cancer | 04/17 | 04/17 | | |
NCT02215876: Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer |
|
|
| Withdrawn | 2 | 0 | RoW | Doxorubicin, Cyclophosphamide, Eribulin | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Breast Cancer | 08/17 | 03/20 | | |
NCT03032614: Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients |
|
|
| Withdrawn | 2 | 0 | NA | Carboplatin, Paraplatin, Eribulin, Halaven, E7389, Veliparib, ABT-888 | The University of Texas Health Science Center at San Antonio | Breast Cancer Stage IV, Ovarian Cancer, BRCA1 Mutation, BRCA2 Mutation | 03/19 | 04/20 | | |
NCT01388647: Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer |
|
|
| Terminated | 1/2 | 12 | US | eribulin, eribulin mesylate, HALAVEN, carboplatin, trastuzumab, Herceptin | Vector Oncology, Eisai Inc. | HER-2 Positive Breast Cancer | 06/14 | 09/14 | | |
|
NCT02396433: Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers |
|
|
| Withdrawn | 1/2 | 0 | US | Carboplatin, Paraplatin, Eribulin, Halaven, E7449, PARP inhibitor | The University of Texas Health Science Center at San Antonio | Cancer of the Breast | 04/15 | 04/15 | | |
| Completed | 1/2 | 41 | Europe | PQR309, Eribulin, eribulin mesylate, Halaven® | PIQUR Therapeutics AG, Hospital Universitario Ramon y Cajal, Hospital Universitari Vall d'Hebron Research Institute, Institut Català d'Oncologia, Churchill Hospital, Barts Cancer Institute, Fundación Instituto Valenciano de Oncología | Metastatic Breast Cancer | 10/18 | 10/18 | | |
